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Oral capecitabine (Xeloda
s) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-
based therapy is becoming standard for Dukes’ C colon cancer in patients suitable for combination therapy, but is not yet approved
by the UK National Institute for Health and Clinical Excellence (NICE) in the adjuvant setting. Adjuvant capecitabine is at least as
effective as 5-fluorouracil/leucovorin (5-FU/LV), with significant superiority in relapse-free survival and a trend towards improved
disease-free and overall survival. We assessed the cost-effectiveness of adjuvant capecitabine from payer (UK National Health Service
(NHS)) and societal perspectives. We used clinical trial data and published sources to estimate incremental direct and societal costs
and gains in quality-adjusted life months (QALMs). Acquisition costs were higher for capecitabine than 5-FU/LV, but higher 5-FU/LV
administration costs resulted in 57% lower chemotherapy costs for capecitabine. Capecitabine vs 5-FU/LV-associated adverse events
required fewer medications and hospitalisations (cost savings d3653). Societal costs, including patient travel/time costs, were reduced
by 475% with capecitabine vs 5-FU/LV (cost savings d1318), with lifetime gain in QALMs of 9 months. Medical resource utilisation is
significantly decreased with capecitabine vs 5-FU/LV, with cost savings to the NHS and society. Capecitabine is also projected to
increase life expectancy vs 5-FU/LV. Cost savings and better outcomes make capecitabine a preferred adjuvant therapy for Dukes’ C
colon cancer. This pharmacoeconomic analysis strongly supports replacing 5-FU/LV with capecitabine in the adjuvant treatment of
colon cancer in the UK.
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The current global standard adjuvant treatment for Dukes’ C (stage
III) colon cancer is intravenous (i.v.) administration of bolus
5-fluorouracil (5-FU) and leucovorin (LV), either weekly or
monthly, over a period of 6–8 months (Van Cutsem et al, 2002).
Adjuvant 5-FU/LV reduces the risk of relapse and prolongs
survival in patients with resected colon cancer (IMPACT, 1995;
O’Connell et al, 1997; Haller et al, 1998; Wolmark et al, 1999;
Porschen et al, 2001; Arkenau et al, 2003).
Although the clinical benefits associated with adjuvant 5-FU/LV
are significant, it is clear that more effective, convenient and
better-tolerated treatments are required. Capecitabine (Xeloda
s,
F Hoffmann-La Roche, Basel, Switzerland) is a convenient oral
fluoropyrimidine that generates 5-FU preferentially in tumour
tissue through a three-step enzymatic cascade (Miwa et al, 1998).
As first-line therapy for metastatic colorectal cancer, oral
capecitabine achieved improved response rates (26 vs 17%,
respectively), and equivalent progression-free and overall survival
compared with monthly bolus i.v. 5-FU/LV (Van Cutsem et al,
Received 4 November 2005; revised 23 February 2006; accepted 27
February 2006
*Correspondence: Professor J Cassidy;
E-mail: j.cassidy@beatson.gla.ac.uk
British Journal of Cancer (2006) 94, 1122–1129
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s2004). Capecitabine was also better tolerated than 5-FU/LV and its
administration was associated with a reduced consumption of
medical resources (Twelves et al, 2001). These results led to the
approval of capecitabine in 2001 as a first-line alternative to 5-FU/
LV in metastatic colorectal cancer.
The effectiveness of capecitabine in the metastatic setting
provided a rationale for its use as adjuvant therapy for colon
cancer. A large, randomised phase III study (X-ACT) was
undertaken to compare the efficacy and tolerability of adjuvant
oral capecitabine vs bolus i.v. 5-FU/LV (Mayo Clinic regimen) over
24 weeks in 1987 patients with Dukes’ C colon cancer (Twelves
et al, 2005). This study demonstrated that capecitabine is at least as
effective as 5-FU/LV with significant superiority in relapse-free
survival (P¼0.0407) and a trend towards improved disease-free
(P¼0.0528) and overall survival (P¼0.0706). In addition, an
improved safety profile was noted in favour of capecitabine
(Scheithauer et al, 2003; Twelves et al, 2005).
On 31 March 2005, capecitabine received approval for the
adjuvant treatment of Dukes’ C colon cancer from the European
Medicines Agency (EMEA) Committee for Medicinal Products for
Human Use (CHMP). Capecitabine was also recently approved as a
single agent for the adjuvant treatment of Dukes’ C colon cancer by
the US Food and Drug Administration (FDA) in patients ‘who have
undergone complete resection of the primary tumour, when
treatment with fluoropyrimidine therapy alone is preferred’.
Patients have long expressed a preference for oral fluoropyrimi-
dine therapy instead of i.v. treatment (Liu et al, 1997; Borner et al,
2002) and oncologists in Europe and the US are now in a better
position to satisfy this preference.
Clearly, the results of the X-ACT trial suggest that capecitabine
can be used instead of 5-FU/LV in the adjuvant treatment
of Dukes’ C colon cancer, and we have seen that oral treatment
is preferable from the point of view of most patients. However,
with ever-increasing pressures to control medical costs, the
decision of whether or not to use a treatment may not be
based on clinical effectiveness alone. Medical guidelines and
treatment decision-making increasingly give consideration to
economic costs associated with achieving the health benefits of a
therapy. The National Institute for Health and Clinical Excellence
(NICE), for example, considers ‘how well the medicine or
treatment works in relation to how much it costs the National
Health Service (NHS)’ (NICE, 2005). These comparisons of cost-
effectiveness can reveal the balance between costs and savings
among alternative treatments and thereby assist healthcare
providers in prioritising use of available medical resources to
maximise health gain (Siegel et al, 1996; Weinstein et al, 1996).
Using data collected prospectively during the X-ACT trial, we
undertook this pharmacoeconomic analysis to evaluate the cost-
effectiveness of adjuvant capecitabine vs standard adjuvant
therapy (bolus 5-FU/LV (Mayo Clinic regimen)) in patients with
Dukes’ C colon cancer, from the UK NHS perspective, as well as
from a societal perspective.
PATIENTS AND METHODS
Medical resource use and cost-effectiveness analyses were
conducted as part of a prospective pharmacoeconomic evalua-
tion of the X-ACT study. In brief, the X-ACT study was an
open-label, multinational, randomised, phase III trial of adjuvant
therapy for resected, histologically confirmed Dukes’ C
colon carcinoma (Scheithauer et al, 2003; Twelves et al, 2005).
Patients were randomised to 24 weeks’ treatment with either eight
cycles of oral capecitabine 1250mgm
 2 twice daily, days 1–14
every 21 days (n¼1004), or six cycles of rapid-infusion i.v.
leucovorin 20mgm
 2 followed immediately by i.v. bolus 5-FU
425mgm
 2, days 1–5 every 28 days (Mayo Clinic regimen)
(n¼983).
Design and structure of the pharmacoeconomic model
A health-state transition model was developed to assess healthcare
costs, quality-adjusted survival and overall cost-effectiveness of
capecitabine compared with 5-FU/LV. The model consists of three
health states – stable (prerelapse; disease- and relapse-free),
postrelapse and death, with further subclassification of the
postrelapse category into relapse (i.e. during subsequent treatment
for metastatic colon cancer), remission and the 12-month period
before death. A relapse event was classified as instances of relapse,
new colon cancer or death due to colon cancer or treatment. These
health states allowed us, in effect, to partition overall survival into
pre- and postrelapse periods, using the relapse-free and overall
survival data for capecitabine and 5-FU/LV observed in the X-ACT
clinical trial. The model incorporates costs during chemotherapy
using the medical resource utilisation data collected during the
X-ACT clinical trial. In addition, possible outcomes for post-
chemotherapy costs were considered for the postrelapse health
states.
The time spent in each health state was estimated by
extrapolating the relapse-free and overall survival follow-up data
from the X-ACT clinical trial to a lifetime horizon. Health
outcomes were measured as life months (LMs) gained and
quality-adjusted life months (QALMs) gained, where QALMs are
a measure of the time spent in each health state, weighted by the
quality of life (utility) in that health state. The incremental cost-
effectiveness ratio, measured as the cost per QALM gained, was
estimated by dividing the difference in total costs in each arm by
the increase in survival for treatment with capecitabine compared
with 5-FU/LV. Technically, a meaningful incremental cost-effec-
tiveness ratio cannot be calculated if a therapy being evaluated is
found to be cost saving or cost neutral (i.e. negative or zero
numerator) and either more or equally effective (i.e. positive or
zero denominator). When a therapy is cost saving and more
effective, it is termed ‘dominant’ because it is clearly preferred.
Table 1 Unit cost estimates for medical resource utilisation
Capecitabine (d) 5FU/LV (d)
Chemotherapy per g
a 4.93 382.20
Visits for drug administration
Physician consultation
b 57 57
i.v. administration visit
c 0 169
Hospitalisation: cost per day
b
354
Provider consultations
GP (office)
b
21
GP (home visit)
b
65
Specialist (office)
b
57
Day care
b
169
Accident and emergency
b
83
Nurse/other office consultation
b
9
Nurse/other home visit
b
20
Ambulance (round trip)
b
86
aMonthly Index of Medical Specialties, September, 2004.
bNetten and Curtis, 2004.
cChartered Institute of Public Finance and Accountancy, 2005.
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The unit costs for medical resource utilisation during treatment
are detailed in Table 1. Safety and medical resource use data were
collected prospectively during the X-ACT clinical trial, throughout
treatment and for 28 days after the last intake of study drug. Data
were recorded at all study centres on case report forms. Data were
collected on study drug administration (including cumulative
dose, infusion duration and frequency), hospital admissions
(including length of stay) and visits to providers and outpatient
consultations for treatment-related adverse events (AEs). Con-
sultations were categorised according to the type of healthcare
provider (e.g. general practitioner, specialist or allied health
professional) and location (e.g. emergency unit, home visit or
clinic visit). It was assumed, based on expert opinion, that 5% of
patient visits to hospital would have required ambulance
transportation.
Chemotherapy drug costs were taken from the Monthly Index of
Medical Specialties (September 2004), with costs for consultations,
hospitalisations, accident and emergency care and ambulance
transportation derived from Unit Costs of Health and Social Care
published by the UK-based Personal Social Services Research Unit
(Netten and Curtis, 2004). Cost of i.v. administration was taken
from the UK Department of Health National Tariff (DOH, 2005).
In the UK, patients receiving capecitabine see a specialist for a
consultation and patients treated with 5-FU/LV go to an outpatient
clinic in a hospital for i.v. administration. In addition, patients
receiving 5-FU/LV will see a specialist during some of their drug
administration visits. In the base case, it was assumed that 5-FU/
LV patients would see a specialist for the same number of visits
as patients receiving capecitabine, in addition to going to the
outpatient clinic for i.v. administration.
The model also considered drugs used in the management of
treatment-related AEs; the selection of drugs to be included in the
model was based on expert clinical/pharmacist judgement. Within
a class of drugs, the drug most commonly used in the clinical trial
was used to estimate the unit cost in that class. The total cost of
each medication was calculated by multiplying the daily cost of
treatment by the total number of days of treatment used in each
arm. This was then divided by the number of patients in the
relevant treatment arm to provide the mean cost per patient.
Assumptions for the post-treatment costs were based on
previously published lifetime costs of colorectal cancer (Etzioni
et al, 2001; Ramsey et al, 2002). Costs associated with relapse were
based on assumptions derived from a study reporting the cost-
effectiveness of oxaliplatin/5-FU/LV in the adjuvant treatment of
colorectal cancer (Aballe ´a et al, 2005). For the base case, the
assumptions were: d100 monthly maintenance cost during
prerelapse, d25000 average cost during the relapse period, d200
monthly maintenance cost during postrelapse; and d10000 average
cost during the last 12 months of life.
Societal costs
From a societal perspective, the model also considered indirect
costs borne by the patient, such as cost of travel and time for
outpatient and drug administration visits. Time assumptions
included travel time, as well as waiting and encounter time and was
assumed to be 1.5h for outpatient visits for management of AEs,
8h for hospitalisations for management of AEs and 2 and 4h,
respectively, for capecitabine consultation and 5-FU/LV adminis-
tration visits (Twelves, 2003). The value assigned to this time was
d12 per hour based on average hourly compensation in the UK.
This information, together with the number of outpatient, hospital
and drug administration visits in each treatment arm was used to
determine the mean number of hours per patient in each treatment
arm and the cost of this time. For travel costs, a 30-mile round trip
was assumed and was assigned a value of d0.23 per mile. This
information, together with the number of outpatient, hospital and
drug administration visits in each treatment arm was used to
determine the total travel cost per patient in each treatment arm.
Survival analysis
The time a patient spent in each health state was estimated using
partitioned survival analysis of the trial data (intent-to-treat
population), with projections beyond the trial period for 5, 10-year
and lifetime horizons. In effect, this analysis estimates the area
under the time-to-event curves at each horizon for relapse and
overall survival, and then derives the postrelapse time by
subtracting the former from the latter. These extrapolations were
based on fitting a log-normal distribution to the relapse-free and
overall survival data for the capecitabine and 5-FU/LV treatment
groups. These data were used to determine the amount of time that
the average patient would spend in the pre- and postrelapse health
states.
Quality of life (utility)
Utility values for the health states were derived from the published
literature (Ramsey et al, 2000). For both arms, it was assumed that
utility was 0.8 during chemotherapy and was 0.86 during the stable
(prerelapse) health state. An overall average utility of 0.59 was
assumed for the postrelapse health states.
Discounting
Discounting for the time value of money was applied to both cost
and outcomes, according to the guidelines issued by the NICE, in
order to compare alternative future levels of costs and benefits.
In this analysis, an annual discount rate of 1.5% was applied to
benefits and an annual discount rate of 6.0% was applied to all
costs.
Sensitivity analyses
One-way and multi-way sensitivity analyses were performed to test
the robustness of the model. The sensitivity analyses widely varied
key assumptions in the model, including time horizon, key cost
parameters (during treatment and post-treatment) and overall
cost-effectiveness.
RESULTS
From November 1998 to November 2001, a total of 1987 patients
were enrolled into the X-ACT study at 164 centres worldwide. The
capecitabine and 5-FU/LV treatment arms included 1004 and 983
patients, respectively, and the treatment arms were well balanced.
The efficacy and safety results have been reported previously
(Scheithauer et al, 2003; Twelves et al, 2005).
3000
2000
1000
0
M
e
a
n
 
n
u
m
b
e
r
 
p
e
r
1
0
0
 
p
a
t
i
e
n
t
s
735
2800
Capecitabine (n=995)
5-FU/LV (n=974)
Figure 1 Number of treatment visits for chemotherapy administration
or AEs with capecitabine vs 5-FU/LV.
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Although the mean cost of chemotherapy drugs per patient was
higher in the capecitabine arm (d2081 compared with d602 in the
5-FU/LV arm), the mean number of treatment administration
visits was increased almost four-fold with the i.v. 5-FU/LV regimen
(28 visits in 6 months) compared with capecitabine (7.4 visits in
6 months) (Figure 1). This resulted in increased costs for
chemotherapy administration in the 5-FU/LV arm compared with
the capecitabine treatment arm (d5151 and d419, respectively).
Thus, considering both drugs and their administration, chemo-
therapy costs are lower by d3253 (57% lower) for capecitabine
vs 5-FU/LV.
Cost of managing AEs
The improved safety profile with capecitabine compared with
5-FU/LV was reflected in the need for fewer costly medications for
the management of treatment-related AEs in the capecitabine
treatment arm compared with 5-FU/LV (Table 2). In particular,
capecitabine reduced the need for the more expensive drugs,
such as fluconazole for stomatitis, 5-HT3 antagonists for nausea/
vomiting and cytokines for neutropenia. Overall, the mean cost
of medication for management of AEs was lower in the
capecitabine arm compared with the 5-FU/LV arm (d86 and
d345, respectively).
A similar mean number of physician visits due to AEs were seen
in each treatment arm (1.93 and 1.92 for capecitabine and i.v.
5-FU/LV, respectively). However, there were 16% fewer AE-related
hospital admissions and 15% fewer days in hospital in the
capecitabine treatment arm vs the i.v. 5-FU/LV arm (10.6 and 12.8
admissions, respectively, and 113 vs 130 days, respectively;
Figure 2). The mean cost of hospitalisations was consequently
lower with capecitabine than with 5-FU/LV (d399 vs d459),
although the cost of physician consultations was slightly increased
with capecitabine compared with 5-FU/LV (d154 vs d145). In
accordance with these findings, the projected ambulance costs
would be reduced in the capecitabine group compared with the
5-FU/LV group (d38 vs d126).
Societal costs for time and travel
The projected mean number of hours per patient required for
travel were lower in the capecitabine group compared with the
5-FU/LV group (27 and 125h, respectively) and the mean costs for
travel time were therefore reduced in the capecitabine group (d320
compared with d1503 in the 5-FU/LV group). Similarly, the mean
travel cost per patient was reduced with capecitabine compared
with 5-FU/LV (d62 and d196, respectively).
Total costs
Direct costs during the treatment period have been grouped into
six components, as illustrated in Table 3. The major drivers for the
cost analysis are the cost of the chemotherapy drugs and the cost
of administration of treatment. The additional d4732 required for
i.v. therapy is more than three times the additional acquisition cost
of capecitabine. With respect to the management of AEs, the most
notable difference was the lower cost of medication used for
treating AEs in the capecitabine arm (d86 compared with d345 in
the 5-FU/LV arm). Overall, from an NHS perspective during the
treatment period alone, oral treatment with capecitabine is
projected to be cost saving by an average amount of approximately
d3653 per patient. From a societal perspective, capecitabine
treatment was associated with cost savings of d1184 and d134
for time and travel costs, respectively, yielding cost savings per
patient of approximately d4971.
Considering post-treatment costs as well as costs during
treatment, the projected direct cost saving for the NHS from a
lifetime perspective is projected to be d3608 per patient. From a
societal perspective, the lifetime cost savings are even greater:
d4925 per patient.
Table 2 Medications used for management of treatment-related adverse
events
Days of use per 100 patients
Medication Capecitabine (n¼995) 5-FU/LV (n¼974)
Antiemetics/antidiarrhoeals 1933 2534
Dermatologicals/emollients 951 229
Benzodiazapines 152 245
Stomatologicals/triazoles 140 775
Antibiotics/cephalosporins 128 133
Cytokines/growth factors 5 21
Octreotide 8 8
Total 3317 3945
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Figure 2 Hospital admissions for AEs.
Table 3 Results of the cost-effectiveness analysis: costs during treatment
Cost impact of capecitabine
treatment for colorectal cancer in
adjuvant therapy (per patient) d
Capecitabine 5-FU/LV
Net cost
savings
Direct medical costs to the NHS
Cost of chemotherapy drugs 2081 602  1479
Cost of visits for study drug
administration
419 5151 4732
Cost of hospital use 399 459 61
Cost of physician consultations
for adverse events
154 145  9
Cost of medication for treating
adverse events
86 345 260
Cost of ambulance trips 38 126 88
Subtotal
a 3176 6829 3653
Societal costs
Cost of time 319 1503 1184
Cost of travel 62 196 134
Total costs
a 3557 8528 4971
aNumbers may differ because of rounding.
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In terms of overall survival, the Kaplan–Meier projection was
81.3% of patients receiving capecitabine surviving at 36 months
compared with 77.6% of patients receiving i.v. 5-FU/LV, an
absolute difference of 3.7%. In the fitted model, the projected
survival gains with capecitabine by 36 and 48 months were 0.5
QALMs and 0.8 QALMs, respectively (Figure 3). When the fitted
model is used to extrapolate to longer horizons, for example,
5 years, 10 years or lifetime, the projected gain in QALMs
continues to increase with capecitabine, even after taking into
account adjustments for quality of life and discounting. Over a
lifetime, for example, the QALM advantage for capecitabine widens
to 9 months.
Sensitivity analyses
Table 4 shows the impact of varying model estimates on short-
term costs and QALMs. Varying drug acquisition costs for study
drugs and medications for management of AEs had only a
marginal effect on short-term cost savings: the total cost savings
were d14 637 and d14 590 at the 5th and 95th percentiles,
respectively. A 20% variation in cost per drug administration visit,
however, yielded an almost two-fold variation (d4577–d2707).
Overall, the sensitivity analyses confirmed substantial cost savings
for oral capecitabine vs 5-FU/LV. These analyses also confirmed
that the substantial QALM advantage for capecitabine vs 5-FU/LV
would be maintained even in the face of variation of health state
utilities and the discount rate for costs and benefits.
The results of the multi-way sensitivity analysis for post-
treatment costs are shown in Table 5. These results demonstrate
that the long-term cost advantages of capecitabine are lowest when
the costs of relapse and maintenance are low. It is clear that even
under rigorous multi-way sensitivity testing, capecitabine remains
a robust, cost-saving treatment option compared with 5-FU/LV.
DISCUSSION
From a UK NHS perspective, this pharmacoeconomic analysis
projects that the use of capecitabine for adjuvant treatment of
colon cancer would not only save direct medical costs, but also
improve health outcomes compared with 5-FU/LV. In economic
terms, capecitabine would be termed a ‘dominant’ (cost saving and
more effective) treatment strategy, taking its place among other
cost-effectiveness benchmarks in oncology (Table 6). The im-
mediate savings on NHS costs during the treatment period with
capecitabine would be approximately d3700 per patient. From a
societal perspective that also considers patient time and travel
costs, the savings would increase to nearly d5000 per patient. In
addition, the projected 3.7% absolute improvement in the patient
survival outcome observed during the trial period should yield an
equivalent of over 9 months of additional survival over a lifetime,
after discounting for the time value of money and adjusting for
possible quality of life changes due to later relapse.
The key drivers of the dominant cost-effectiveness results of
capecitabine in comparison with 5-FU/LV are firstly the savings
achieved by avoiding the cost of the i.v. Mayo Clinic regimen for
5-FU/LV, and secondly the projection of improved survival. These
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Figure 3 Net gain with capecitabine compared with 5-FU/LV in QALMs
by model horizon.
Table 4 Results of one-way sensitivity analyses
Parameter Range Short-term cost savings Lifetime QALMs
Mean mg of capecitabine use 430137–414180 d3614–d3693 No change–No change
Mean mg of 5-FU use 19820–19147 d3658–d3649 No change–No change
Mean mg of LV use 973–937 d3660–d3647 No change–No change
Heath state utilities +20–20% No change–No change 10.9–6.7
Cost per drug administration visit +20–20% d4577–d2707 No change–No change
Discount rate for costs and benefits 3.5% d3899 (long-term cost savings) 6.5
Total AE medication cost +20–20% d3705–d3601 No change–No change
QALMs Weibull distribution No change 10.9
Table 5 Results of multi-way sensitivity analysis for post-treatment costs
Post-treatment cost parameters (d)
Prerelapse
monthly
savings
Relapse
period
Postrelapse
monthly
maintenance
Last year
of life
Lifetime
cost
savings (d)
100 (base case) 25000 200 10000 3608
100 10000 200 5000 2973
200 10000 400 5000 1813
100 40000 200 15000 4242
50 25000 100 10000 4185
50 40000 100 15000 4819
Table 6 Cost-effectiveness benchmarks in oncology
Cancer setting
Life-expectancy
gain (months)
Cost per life
year gained
Capecitabine vs 5-FU/LV Colon adjuvant 8.7
a Dominant
b
FOLFIRI vs 5-FU/LV
c Colorectal
metastatic
2.6 d29000
AT vs AC
c Breast metastatic NA d19000
CMF vs observation
d Breast adjuvant 3.6 US$447
Chemotherapy vs
observation
e
Breast adjuvant 5.1
a US$15400
a
NA¼not available.
aQuality-adjusted values.
bCost saving and more effective in terms
of quality-adjusted life months.
cNational Institute for Health and Clinical Excellence.
dMessori et al, 1996.
eHillner and Smith, 1991.
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sare both substantial benefits in comparison to the acquisition cost
of capecitabine. The favourable safety profile of capecitabine also
translates into lower costs for AEs due to fewer hospitalisations
and lower associated medication costs. However, considering costs
after the treatment period essentially has a cost neutral impact in
the base case: the additional costs of living longer on capecitabine
are about the same as the additional costs of earlier and more
frequent relapses and death on 5-FU/LV.
In the short term, the critical comparison is between the higher
drug acquisition cost of capecitabine (d2081 compared with d602
for 5-FU/LV) and the additional costs for the 28 5-FU/LV infusions
(d4732) received by the average patient in the 5-FU/LV treatment
arm of the X-ACT trial. We assume that these are provided in an
outpatient setting in the UK and that the cost to the NHS is d169
per administration. However, even if the infusion administration
costs were as little as one-half of this value, the cost would still be
greater than the acquisition cost of capecitabine.
The way in which funding is provided in NHS hospitals, for
example, reimbursement for day case attendances, provides some
disincentive for them to take a broader NHS perspective, much less
the even broader societal perspective. Nonetheless prescribing
committees, hospitals and other policy makers should be
encouraged to take a broader perspective. Tight prescribing
budgets can mean that acquiring approval to switch to capecita-
bine is difficult but the additional benefits for patients should be
weighed in any such decision. Furthermore, although staff costs
may be fixed, freeing up their time will allow them to treat more
cancer patients quickly and thereby help to reduce waiting lists to
government targets.
The other key driver in assessing cost-effectiveness is the
projection of improved survival. Although there was only a strong
statistical trend towards a survival advantage in the X-ACT trial at
3 years of follow-up, it is important to consider the corroborating
evidence. First, the projected survival advantage is reflected in all
three, presumably related, measures of disease-free, relapse-free
and overall survival (Sargent, 2004). Second, the correlation among
these is consistent with previous studies of adjuvant 5-FU/LV in
colon cancer. Third, the outcome in the control arm is similar to
previous studies using the Mayo Clinic regimen (Haller et al,
1998). Furthermore, the strength of the statistical trend was
reinforced by the finding that covariate-adjusted survival was
significantly superior with capecitabine vs 5-FU/LV (hazard ratio
0.788, P¼0.0208; Twelves et al, 2005).
The estimation of the quantitative impact on survival required
extrapolation beyond the observed trial period. In similar studies,
investigators have approached this in a variety of ways; there is no
uniform methodology. We used the approach of fitting a curve to
the observed data and extrapolating to the end of life. Both the
log-normal and Weibull survival curves are commonly used for
this, so both were tried. The fit during the trial period was slightly
better for the log-normal curve so this was used in the base case.
However, the log-normal distribution yielded a gain of nine
QALMs, while the Weibull distribution produced 10.9 QALMs,
suggesting that the overall survival results were not sensitive to
this choice and were possibly conservative.
The improved survival rates observed with capecitabine,
together with the cost savings identified in this and other analyses,
render it a viable alternative to 5-FU/LV both as a single agent and
in combination. Preliminary phase III data have shown the
combination of oxaliplatin and infusional 5-FU/LV (FOLFOX) to
be effective in the adjuvant setting (Arkenau et al, 2005; Ducreux
et al, 2005; Sastre et al, 2005). Replacing 5-FU/LV with
capecitabine in this combination is promising not only clinically,
but also economically, as additional infusion and time costs would
be avoided.
One limitation of this model is the lack of direct measures of
utility in the stable (prerelapse) health state following treatment.
Based on the literature, we imputed a relatively high utility value of
0.86 for this health state, which was assumed for both arms. Thus,
any impact would be due to the duration of time in this health
state, vs the time in the postrelapse health state. The postrelapse
value was also imputed from the literature to be 0.59, which is
similar to the values reported for patients on chronic renal dialysis.
Treatment phase utility was assumed to be the same in both arms:
0.80.
The use of a societal perspective to measure the time and travel
costs associated with the treatments illustrates the advantage of
oral over infusion treatment. On average, patients receiving oral
therapy are estimated to spend around 99 fewer hours either
receiving treatment or in treatment-related travel. Valued at
average market compensation, this amounts to an additional cost
saving of about d1300, which is treated here as a cost to society. It
could well be the case that many patients would also regard this
impact as representing some degree of utility loss with infusion
therapy, reflecting a negative impact on their quality of life during
the treatment period. The calculations do not take account of such
an effect: only the opportunity cost of the time spent is projected.
This pharmacoeconomic analysis found that capecitabine is a
dominant (cost saving and more effective) therapy compared with
5-FU/LV from both the NHS and societal perspectives. These
results are further supported by other analyses in the Italian
healthcare setting, where capecitabine was also found to be cost
saving by h2234 per adjuvant treatment (data on file) and in the
US, where capecitabine was projected to be a cost-effective therapy
from a payer and societal perspective (Garrison et al, 2005). Based
on these data, the replacement of 5-FU/LV with capecitabine in the
adjuvant treatment of colon cancer in the UK would be cost saving
and produce better outcomes and hence be strongly cost-effective
and preferred.
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Appendix A
The following investigators participated in this study:
Argentina – E Mickiewicz, G Pallotta, E Roca, MS Varela,
RC Wainstein
Australia – E Abdi, A Barling, S Begbie, D Bell, R Blum,
WI Burns, P de Souza, D Kotasek, J Levi, K Pittman, M Schwarz,
C Underhill, D Wyld
Austria – P Balcke, M Baur, D Geissler, P Kier, H Ludwig,
K Mach, D O ¨fner, M Prager, H Steiner
Belgium – J De Gre `ve, D Vanstraelen
Brazil – L Camillo-Coura, G Delgado, S Lago, C Rotstein
Canada – JP Ayoub, O Keller, K Khoo, R Rajan, A Sami, R Wong
Croatia – M Duvnjak, ZK Osijek, R Ostojic, E Vrdoljak
Czech Republic – J Dvorak, J Fı ´nek, I Kocakova, M Ku ˚ta,
J Nemec, V Svoboda, P Vodvarka
France – FX Caroli-Bosc, G Dabouis, E Gamelin, JL Gaudin,
M Giovannini, H Gouerou, JE Kurtz, C Lombard-Bohas,
D Pere ´-Verge ´, M Ychou
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sGermany – W Abenhardt, R Behrens, W Brugger,
R Heinze, WD Hirschmann, KW Jauch, E Kettner, B Otremba,
H Riess, J Ru ¨schoff, M Schmidt, H Tesch, B Tschechne,
M Wolf
Greece – L Boutis, I Katsos, G Panagos
Israel – D Aderka, A Benni, B Klein, A Shani, S Stemmer
Italy – M Airoldi, G Amadori, M Antimi, C Barone,
M Bertuccelli, G Biasco, C Bumma, G Comella, P Conte,
F Di Costanzo, CM Foggi, V Fosser, S Frustaci, G Gasparini,
R Labianca, G Luppi, M Marco, D Mecarocci, A Paccagnella,
C Rabbi, S Ricci, A Scanni, V Silingardi, F Smerieri,
O Vinante
Latvia – A Brı ˆze, G Purkalne
Poland – M Foszczynska-Kloda
Portugal – P Cortes, B da Costa, J Maurı ´cio, E Sanches
Spain – E Aranda, R Cubedo, A Lozano, H Manzano, P Martinez
del Prado, R Pe ´rez Carrio ´n, G Pe ´rez-Manga, JJ Valerdi, JJ Valverde,
A Velasco
Sweden – G Borghede, H Gro ¨nberg, B Gustavson, T Linne ´,
BL o ¨de ´n, B. Norberg, H Starkhammar, J-H Svensson
Switzerland – M Borner, R Hermann, D Ko ¨berle, R Morant,
O Pagani, C Sessa, R Stahel
Thailand – S Chakrapee-Sirisuk
United Kingdom – N Bailey, F Daniel, D Dunlop, T Iveson,
R James, E Levine, A Makris, A McDonald, L Samuel, M Soukop,
W Steward, C Topham
Uruguay – IM Muse
USA – J Eckardt, G Gross, G Justice, L Kalman, R Kerr,
CG Leichman, E Levine, V Malhotra, R Pelley, MC Perry, J Posey,
M Saleh, J Salvatore, J Wooldridge
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